The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?
EQ Roldan, G Biasiotto, P Magro, I Zanella - Pharmacological research, 2020 - Elsevier
The anti-malarial drugs chloroquine (CQ) and primarily the less toxic hydroxychloroquine
(HCQ) are currently used to treat autoimmune diseases for their immunomodulatory and anti …
(HCQ) are currently used to treat autoimmune diseases for their immunomodulatory and anti …
The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: a pilot open label randomized …
E Kravvariti, A Koutsogianni, E Samoli, PP Sfikakis… - Autoimmunity …, 2020 - Elsevier
Background Sporadic studies suggest hydroxychloroquine (HCQ) may be effective for
thrombosis prevention in patients with primary antiphospholipid syndrome (PAPS) and may …
thrombosis prevention in patients with primary antiphospholipid syndrome (PAPS) and may …
EULAR recommendations for the management of antiphospholipid syndrome in adults
MG Tektonidou, L Andreoli, M Limper… - Annals of the …, 2019 - ard.bmj.com
The objective was to develop evidence-based recommendations for the management of
antiphospholipid syndrome (APS) in adults. Based on evidence from a systematic literature …
antiphospholipid syndrome (APS) in adults. Based on evidence from a systematic literature …
[HTML][HTML] Aspirin: the mechanism of action revisited in the context of pregnancy complications
AP Cadavid - Frontiers in immunology, 2017 - frontiersin.org
Aspirin is one of the most frequently used and cheapest drugs in medicine. It belongs to the
non-steroidal anti-inflammatory drugs with a wide range of pharmacological activities …
non-steroidal anti-inflammatory drugs with a wide range of pharmacological activities …
[HTML][HTML] Antiphospholipid syndrome and the neurologist: from pathogenesis to therapy
T Fleetwood, R Cantello, C Comi - Frontiers in neurology, 2018 - frontiersin.org
Antiphospholipid syndrome (APS) is an autoimmune antibody-mediated condition
characterized by thrombotic events and/or pregnancy morbidity in association with persistent …
characterized by thrombotic events and/or pregnancy morbidity in association with persistent …
An update on antiphospholipid syndrome
E Xourgia, MG Tektonidou - Current Rheumatology Reports, 2021 - Springer
Abstract Purpose of Review To review the recent available evidence on epidemiology,
pathogenesis, clinical phenotypes, and management of antiphospholipid syndrome (APS) …
pathogenesis, clinical phenotypes, and management of antiphospholipid syndrome (APS) …
HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome
C Belizna, F Pregnolato, S Abad, J Alijotas-Reig… - Autoimmunity …, 2018 - Elsevier
The relapse rate in antiphospholipid syndrome (APS) remains high, ie around 20%–21% at
5 years in thrombotic APS and 20–28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) …
5 years in thrombotic APS and 20–28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) …
Neurologic manifestations of antiphospholipid syndrome
IF Ricarte, LA Dutra, FF Abrantes, FF Toso… - Lupus, 2018 - journals.sagepub.com
Neurological involvement in antiphospholipid antibody syndrome (APS) is common, and its
occurrence increases morbidity and mortality. Patients may present variable neurological …
occurrence increases morbidity and mortality. Patients may present variable neurological …
[HTML][HTML] Type I interferon signature in primary antiphospholipid syndrome: clinical and laboratory associations
E Palli, E Kravvariti, MG Tektonidou - Frontiers in Immunology, 2019 - frontiersin.org
Background: Increased expression of type I interferon (IFN)-regulated genes has been
described in blood and tissue cells from patients with systemic lupus erythematosus (SLE) …
described in blood and tissue cells from patients with systemic lupus erythematosus (SLE) …
Management of non-criteria manifestations in antiphospholipid syndrome
E Xourgia, MG Tektonidou - Current Rheumatology Reports, 2020 - Springer
Abstract Purpose of the Review To review the available evidence on the management of a
variety of non-criteria manifestations in antiphospholipid syndrome (APS), including valvular …
variety of non-criteria manifestations in antiphospholipid syndrome (APS), including valvular …